Enzalutamide tablet

DRUG2 trials

Sponsors

Astellas Pharma Europe B.V., Jiangsu HengRui Medicine Co., Ltd.

Conditions

Pharmacokinetics of EnzalutamideProstate Cancer

Phase 1

Relative Bioavailability Study of Enzalutamide in Prostate Cancer Patients

CompletedNCT01902251

Astellas Pharma Europe B.V.Pharmacokinetics of Enzalutamide, Prostate Cancer

Start: 2012-11-30End: 2013-10-31Updated: 2014-09-09

Phase 2

A Study of SHR3680, HS-20093 and SHR2554 in Subjects With Prostate Cancer

RecruitingNCT07230106

Jiangsu HengRui Medicine Co., Ltd.Prostate Cancer

Start: 2025-12-08End: 2029-12-01Target: 218Updated: 2026-03-03

Related Papers

Safety of continued administration of enzalutamide in patients with prostate cancer who showed benefit from prior exposure: A phase 2 open-label extension study.

Journal of Clinical Oncology2018-02-201 citations